



Jackson Hole Fire/EMS Operations Manual

Approved by: Will Smith
Will Smith, MD, Medical Director

Approved by: Brady Hansen
Brady Hansen, Fire Chief

Title: **Medication Protocol:
Sufentanil (Dsuvia)**
Division: 17
Article: 1.37
Revised: December, 2019
Pages: 2

Sufentanil (Dsuvia) (Medication Protocol)

PARAMEDIC PROVIDERS

STANDING ORDER

CLASS: Opioid analgesic

PHARMACOLOGY/ ACTIONS: Sufentanil is a synthetic, potent opioid with highly selective binding to μ -opioid receptors and exerts its principal pharmacologic effects on the central nervous system. Its primary therapeutic actions are analgesia and sedation. This drug depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. **Sufentanil is metabolized by hepatic enzyme CYP3A4 and produces no active metabolites.**

ONSET/DURATION: Onset: 10-15 minutes / Duration: 1-2 hours

USE IN FIELD/ INDICATIONS:

- Management of acute pain
- Intended to be a simple, effective, non-invasive analgesic option until provider can establish reliable intravenous access.
- Sufentanil rapidly penetrates and affects CNS

CONTRAINDICATIONS:

- Known hypersensitivity to sufentanil
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus

SIDE EFFECTS: Although majority of patients exhibit no side effects. Adverse side effects can include:

- Nausea & Vomiting
- Somnolence, Oxygen desaturation
- Dizziness
- Headache
- Hypotension

DRUG INTERACTIONS:

- Central nervous system depressants (e.g., **alcohol, benzodiazepines, other opioids**)
- Serotonergic drugs (e.g., **SSRIs, tramadol, MAO inhibitors**)
- CYP3A4 inducers (e.g., **rifampin, carbamazepine, phenytoin**)
- CYP3A4 inhibitors (e.g., **erythromycin, ketoconazole, ritonavir**)

ROUTE: Sublingual.

| DOSAGE: | ADULT | PEDIATRIC (<45 kg) |
|----------------|---------------------------------------------------------------------------------------------------------------------------|------------------------------|
| | One 30-mcg tablet delivered from Single-Dose Applicator (SDA). | |
| | Additional analgesia should be provided PRN through administration of other analgesic medications (IV/IO ideally). | NOT INDICATED |
| | In prolonged care consideration additional dosing of 1 (one) 30-mcg tablet at 1 hour. | |

PREGNANCY SAFETY: **Category C** - Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

COMMENTS: Security protocol is the responsibility of Jackson Hole Fire/EMS.

SCHEDULE II NARCOTIC --High potential for abuse.